Trial Profile
Pharmacokinetics of Oral Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alisertib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 15 Apr 2019 Results evaluating the effect of moderate or severe hepatic impairment on pharmacokinetics of the alisertib in adult patients with advanced solid tumors or lymphomapublished in the Journal of Clinical Pharmacology
- 02 Dec 2016 Results presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- 26 Aug 2016 Status changed from recruiting to completed.